CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Genfit SA - GNFTfr CFD

    2.91
    1.36%
    0.14
    Low: 2.88
    High: 2.96
    Market Trading Hours* (UTC) Opens on Thursday at 08:00

    Mon - Fri: 08:00 - 16:30

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.14
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.022082 %
    Charges from full value of position ($-4.20)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.022082%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.00014 %
    Charges from full value of position ($-0.03)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.00014%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency EUR
    Margin 5%
    Stock exchange France
    Commission on trade 0%

    *Information provided by Capital.com

    Genfit SA ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.95
    Open* 2.92
    1-Year Change* -15.61%
    Day's Range* 2.88 - 2.96
    52 wk Range 2.84-4.92
    Average Volume (10 days) 223.72K
    Average Volume (3 months) 5.09M
    Market Cap 152.74M
    P/E Ratio -100.00K
    Shares Outstanding 49.84M
    Revenue 29.75M
    EPS -0.69
    Dividend (Yield %) N/A
    Beta 1.06
    Next Earnings Date Apr 11, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 6, 2023 2.91 0.04 1.39% 2.87 2.96 2.87
    Dec 5, 2023 2.95 0.06 2.08% 2.89 2.98 2.88
    Dec 4, 2023 2.91 -0.09 -3.00% 3.00 3.06 2.91
    Dec 1, 2023 2.94 0.02 0.68% 2.92 3.01 2.92
    Nov 30, 2023 2.98 0.01 0.34% 2.97 3.03 2.93
    Nov 29, 2023 2.93 -0.03 -1.01% 2.96 3.00 2.93
    Nov 28, 2023 2.93 -0.01 -0.34% 2.94 3.00 2.92
    Nov 27, 2023 2.93 0.01 0.34% 2.92 3.00 2.92
    Nov 24, 2023 2.94 0.01 0.34% 2.93 3.08 2.93
    Nov 23, 2023 2.96 0.04 1.37% 2.92 3.02 2.92
    Nov 22, 2023 3.03 0.06 2.02% 2.97 3.06 2.97
    Nov 21, 2023 3.03 -0.03 -0.98% 3.06 3.12 3.03
    Nov 20, 2023 3.15 0.16 5.35% 2.99 3.17 2.99
    Nov 17, 2023 3.01 -0.04 -1.31% 3.05 3.09 2.98
    Nov 16, 2023 3.05 -0.02 -0.65% 3.07 3.10 2.97
    Nov 15, 2023 3.03 -0.04 -1.30% 3.07 3.17 3.03
    Nov 14, 2023 3.18 -0.04 -1.24% 3.22 3.37 3.11
    Nov 13, 2023 3.19 0.21 7.05% 2.98 3.21 2.98
    Nov 10, 2023 3.02 -0.06 -1.95% 3.08 3.09 3.00
    Nov 9, 2023 3.13 0.06 1.95% 3.07 3.21 3.06

    Genfit SA Events

    Time (UTC) Country Event
    Thursday, April 11, 2024

    Time (UTC)

    14:00

    Country

    FR

    Event

    Full Year 2024 Genfit SA Earnings Release
    Full Year 2024 Genfit SA Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 26.566 85.579 7.758 40.961 7.494
    Revenue 26.566 85.579 7.758 40.961 7.494
    Cost of Revenue, Total 2.124 1.471 2.078 2.194 1.854
    Gross Profit 24.442 84.108 5.68 38.767 5.64
    Total Operating Expense 53.855 18.185 90.655 98.793 76.978
    Selling/General/Admin. Expenses, Total 7.829 8.989 18.154 21.29 4.197
    Research & Development 27.437 27.002 50.771 53.249 57.091
    Depreciation / Amortization 1.48 2.801 1.57 5.25 1.707
    Unusual Expense (Income) -0.016 -35.145 5.388 -0.019 -0.002
    Other Operating Expenses, Total 15.001 13.067 12.694 16.829 12.131
    Operating Income -27.289 67.394 -82.897 -57.832 -69.484
    Interest Income (Expense), Net Non-Operating 2.857 2.032 -18.86 -8.197 -10.8
    Other, Net 0.596 0.048 0.108 0.308 0.409
    Net Income Before Taxes -23.836 69.474 -101.649 -65.721 -79.875
    Net Income After Taxes -23.72 67.259 -101.221 -65.145 -79.521
    Minority Interest 0 0 0 0
    Net Income Before Extra. Items -23.72 67.259 -101.221 -65.145 -79.521
    Net Income -23.72 67.259 -101.221 -65.145 -79.521
    Income Available to Common Excl. Extra. Items -23.719 67.259 -101.221 -65.144 -79.521
    Income Available to Common Incl. Extra. Items -23.719 67.259 -101.221 -65.144 -79.521
    Diluted Net Income -23.719 67.259 -101.221 -65.144 -79.521
    Diluted Weighted Average Shares 49.6739 55.6136 38.8586 36.988 31.1672
    Diluted EPS Excluding Extraordinary Items -0.47749 1.2094 -2.60485 -1.76122 -2.55143
    Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
    Diluted Normalized EPS -0.4777 0.5976 -2.51473 -1.76155 -2.55147
    Total Adjustments to Net Income 0.001 0.001
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total revenue 15.374 14.378 12.188 80.059 3.428
    Revenue 15.374 14.378 12.188 80.059 3.428
    Cost of Revenue, Total 1.202 0.939 1.185 0.756 0.715
    Gross Profit 14.172 13.439 11.003 79.303 2.713
    Total Operating Expense 34.673 27.323 26.532 20.784 -2.599
    Selling/General/Admin. Expenses, Total 4.529 4.104 3.725 4.821 4.168
    Research & Development 20.667 14.01 13.427 7.13 19.872
    Depreciation / Amortization 0.994 0.619 0.963 2.525 0.276
    Unusual Expense (Income) -0.053 -0.017 0.001 0.092 -35.237
    Other Operating Expenses, Total 7.334 7.668 7.231 5.46 7.607
    Operating Income -19.299 -12.945 -14.344 59.275 6.027
    Interest Income (Expense), Net Non-Operating -2.468 -0.999 3.857 1.893 0.139
    Other, Net 1.327 0.467 0.128 0.051 -0.003
    Net Income Before Taxes -20.44 -13.477 -10.359 61.219 6.163
    Net Income After Taxes -20.854 -13.321 -10.399 56.109 9.058
    Net Income Before Extra. Items -20.854 -13.321 -10.399 56.109 9.058
    Net Income -20.854 -13.321 -10.399 56.109 9.058
    Income Available to Common Excl. Extra. Items -20.854 -13.32 -10.399 56.109 9.058
    Income Available to Common Incl. Extra. Items -20.854 -13.32 -10.399 56.109 9.058
    Diluted Net Income -20.854 -13.32 -10.399 56.109 9.058
    Diluted Weighted Average Shares 49.7019 49.6791 49.6687 67.5406 43.6867
    Diluted EPS Excluding Extraordinary Items -0.41958 -0.26812 -0.20937 0.83075 0.20734
    Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
    Diluted Normalized EPS -0.42028 -0.26834 -0.20935 0.83199 -0.31694
    Minority Interest 0
    Total Adjustments to Net Income 0.001
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 158.459 268.097 184.717 290.753 218.116
    Cash and Short Term Investments 140.551 258.756 171.029 276.748 207.24
    Cash 16.91 189.711 4.995 13.601 5.718
    Cash & Equivalents 119.091 69.045 166.034 263.147 201.522
    Short Term Investments 4.55 0
    Total Receivables, Net 15.906 7.236 11.919 12.033 8.794
    Accounts Receivable - Trade, Net 3.188 0.055 0.793 0.206 0.026
    Total Inventory 0.004 0.004 0.004 0.004 0.004
    Prepaid Expenses 1.998 2.101 1.765 1.968 2.078
    Total Assets 215.54 281.72 198.614 309.853 229.478
    Property/Plant/Equipment, Total - Net 8.21 9.015 11.648 16.453 7.764
    Property/Plant/Equipment, Total - Gross 20.794 20.018 24.91 27.238 15.774
    Accumulated Depreciation, Total -12.584 -11.003 -13.262 -10.785 -8.01
    Intangibles, Net 43.957 0.174 0.791 0.92 0.796
    Long Term Investments 4.914 4.431 1.458 1.727 1.313
    Other Long Term Assets, Total 0 0 0 0 0
    Total Current Liabilities 39.37 62.837 31.067 43.657 39.248
    Accounts Payable 8.613 12.304 20.337 32.753 32.649
    Accrued Expenses 4.852 4.103 4.478 3.599 2.969
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 5.066 2.171 4.34 4.529 3.151
    Other Current Liabilities, Total 20.839 44.259 1.912 2.776 0.479
    Total Liabilities 121.012 162.623 214.776 225.788 208.539
    Total Long Term Debt 70.195 72.047 181.343 179.081 163.202
    Long Term Debt 64.668 66.067 173.297 168.912 161.821
    Capital Lease Obligations 5.527 5.98 8.046 10.169 1.381
    Other Liabilities, Total 10.937 27.137 1.599 1.857 4.316
    Total Equity 94.528 119.097 -16.162 84.065 20.939
    Common Stock 12.459 12.454 9.722 9.715 7.796
    Additional Paid-In Capital 444.683 444.438 379.057 377.821 251.554
    Retained Earnings (Accumulated Deficit) -360.291 -336.831 -404.039 -303.007 -237.688
    Treasury Stock - Common -0.978 -0.986 -0.811 -0.477 -0.73
    Other Equity, Total -1.345 0.022 -0.091 0.013 0.007
    Total Liabilities & Shareholders’ Equity 215.54 281.72 198.614 309.853 229.478
    Total Common Shares Outstanding 49.835 49.8155 38.8586 38.8586 31.1839
    Other Current Assets, Total
    Note Receivable - Long Term 0 0.003 0 0 1.489
    Deferred Income Tax 0.51 0.602 0.767 1.193 1.773
    Minority Interest 0 0 0 0
    Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Total Current Assets 134.592 158.459 223.53 268.097 121.283
    Cash and Short Term Investments 111.826 140.551 209.115 258.756 104.379
    Cash 98.042 16.91 53.923 189.711 15.207
    Cash & Equivalents 13.784 119.091 155.192 69.045 89.172
    Total Receivables, Net 20.184 15.906 11.428 7.236 13.842
    Accounts Receivable - Trade, Net 2.787 3.188 0.743 0.055 0.556
    Total Inventory 0.004 0.004 0.004 0.004 0.004
    Prepaid Expenses 2.578 1.998 2.982 2.101 3.058
    Total Assets 193.905 215.54 237.049 281.72 133.712
    Property/Plant/Equipment, Total - Net 8.144 8.21 8.554 9.015 10.328
    Property/Plant/Equipment, Total - Gross 20.794 20.393 20.018 21.992
    Accumulated Depreciation, Total -12.584 -11.839 -11.003 -11.664
    Intangibles, Net 46.182 43.957 0.149 0.174 0.704
    Long Term Investments 4.986 4.914 4.817 4.431 1.398
    Other Long Term Assets, Total 0.001 0 -0.001 0 -0.001
    Total Current Liabilities 45.66 39.37 35.288 62.837 30.964
    Accounts Payable 15.883 8.614 10.23 12.304 23
    Accrued Expenses 3.545 4.852 3.125 4.103 3.943
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 7.741 5.066 2.212 2.171 2.873
    Other Current Liabilities, Total 18.491 20.838 19.721 44.259 1.148
    Total Liabilities 119.385 121.012 127.883 162.623 101.146
    Total Long Term Debt 67.674 70.195 72.499 72.047 64.828
    Long Term Debt 62.649 64.668 66.721 66.067 58.065
    Capital Lease Obligations 5.025 5.527 5.778 5.98 6.763
    Deferred Income Tax 0.491 0.51 0.647 0.602 0.608
    Minority Interest 0 0 0
    Other Liabilities, Total 5.56 10.937 19.449 27.137 4.746
    Total Equity 74.52 94.528 109.166 119.097 32.566
    Common Stock 12.459 12.459 12.454 12.454 11.444
    Additional Paid-In Capital 444.957 444.683 444.586 444.438 416.965
    Retained Earnings (Accumulated Deficit) -380.872 -360.291 -347.005 -336.831 -394.937
    Treasury Stock - Common -0.884 -0.978 -1.05 -0.986 -0.854
    Other Equity, Total -1.14 -1.345 0.181 0.022 -0.052
    Total Liabilities & Shareholders’ Equity 193.905 215.54 237.049 281.72 133.712
    Total Common Shares Outstanding 49.835 49.835 49.8155 49.8155 45.7752
    Note Receivable - Long Term 0 0 0.003
    Other Current Assets, Total 0.001
    Short Term Investments 0 4.55
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -23.719 67.259 -101.221 -65.144 -79.521
    Cash From Operating Activities -72.638 99.915 -96.371 -47.679 -56.08
    Cash From Operating Activities 1.832 2.742 3.559 3.263 1.819
    Non-Cash Items 4.186 -29.766 12.42 14.558 11.194
    Cash Taxes Paid 0.145 0 0 -0.093
    Changes in Working Capital -54.937 59.68 -11.129 -0.356 10.428
    Cash From Investing Activities -46.266 -3.377 -0.966 0.327 -3.986
    Capital Expenditures -0.537 -0.9 -2.03 -2.938
    Other Investing Cash Flow Items, Total -46.266 -2.84 -0.066 2.357 -1.048
    Cash From Financing Activities -3.786 -8.916 -8.256 116.851 -6.514
    Financing Cash Flow Items -2.043 -1.835 -6.32 -7.794 -6.351
    Issuance (Retirement) of Stock, Net 0.005 27.972 0.007 126.529 0.037
    Issuance (Retirement) of Debt, Net -1.748 -35.053 -1.943 -1.884 -0.2
    Net Change in Cash -122.756 87.727 -105.719 69.499 -66.58
    Foreign Exchange Effects -0.066 0.105 -0.126
    Dec 2022 Jun 2022 Dec 2021 Jun 2021
    Net income/Starting Line -23.719 -10.399 67.259 9.058
    Cash From Operating Activities -72.638 -47.499 99.915 -27.81
    Cash From Operating Activities 1.832 0.944 2.742 1.511
    Non-Cash Items 4.186 2.267 -29.766 -36.688
    Cash Taxes Paid 0.145 0 -0.006
    Changes in Working Capital -54.937 -40.311 59.68 -1.691
    Cash From Investing Activities -46.266 -0.199 -3.377 0.215
    Capital Expenditures -0.537 -0.021
    Other Investing Cash Flow Items, Total -46.266 -0.199 -2.84 0.236
    Cash From Financing Activities -3.786 -1.943 -8.916 -38.966
    Financing Cash Flow Items -2.043 -1.04 -1.835 -0.834
    Issuance (Retirement) of Stock, Net 0.005 0 27.972 0
    Issuance (Retirement) of Debt, Net -1.748 -0.903 -35.053 -38.132
    Foreign Exchange Effects -0.066 0 0.105 -0.088
    Net Change in Cash -122.756 -49.641 87.727 -66.649
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Ipsen Pharma SAS Corporation 7.9969 3985239 0 2023-05-04 LOW
    Tang Capital Management, LLC Hedge Fund 4.917 2450404 1076667 2023-07-06 MED
    Biotech Avenir SAS Holding Company 3.7897 1888618 0 2023-05-04 LOW
    Université Lille 2 Corporation 1.3068 651250 0 2023-05-04
    Sunny Asset Management Investment Advisor 0.2207 110000 0 2023-09-30 MED
    CPR Asset Management Investment Advisor 0.2189 109111 0 2023-08-31 MED
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.0892 44474 0 2023-08-31 LOW
    Mandarine Gestion Investment Advisor 0.082 40885 -9115 2023-04-30 LOW
    Mouney (Jean-François) Individual Investor 0.0734 36594 0 2023-05-04 LOW
    Clay Asset Management SAS Investment Advisor 0.0602 30000 30000 2023-06-30 LOW
    Meeschaert Amilton Asset Management Investment Advisor 0.0492 24500 24500 2023-06-30 MED
    Syquant Capital S.A.S Investment Advisor 0.0478 23812 -113906 2022-06-30 MED
    Baillie Gifford & Co. Investment Advisor 0.0465 23168 -24083 2023-07-31 LOW
    Prigent (Pascal) Individual Investor 0.0416 20708 20708 2023-05-04 HIGH
    American Century Investment Management, Inc. Investment Advisor/Hedge Fund 0.0411 20500 256 2023-09-30 LOW
    UNIQA Towarzystwo Funduszy Inwestycyjnych S. A Investment Advisor 0.0249 12400 12400 2022-12-31 MED
    Dimensional Fund Advisors, Ltd. Investment Advisor 0.0231 11487 0 2023-09-30 LOW
    Lannoo (Laurent) Individual Investor 0.0195 9736 9736 2023-04-01
    Hum (Dean W) Individual Investor 0.0165 8204 8204 2023-04-01
    Avantis Investors Investment Advisor 0.0116 5760 -22748 2023-09-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Genfit Company profile

    About Genfit SA

    Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

    Financial summary

    BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).

    Equity composition

    01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).

    Industry: Biotechnology & Medical Research (NEC)

    Parc Eurasanté 885 avenue Eugène Avinée
    LOOS
    HAUTS-DE-FRANCE 59120
    FR

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    US100

    15,793.50 Price
    -0.480% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    BTC/USD

    44,007.60 Price
    +0.170% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,029.48 Price
    +0.510% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    Oil - Crude

    69.91 Price
    -3.200% 1D Chg, %
    Long position overnight fee -0.0207%
    Short position overnight fee -0.0013%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading